The key nuclear export protein CRM1/XPO1 may represent a promising novel therapeutic target in human multiple myeloma (MM). Here we showed that chromosome region maintenance 1 (CRM1) is highly expressed in patients with MM, plasma cell leukemia cells and increased in patient cells resistant to bortezomib treatment. CRM1 expression also correlates with increased lytic bone and shorter survival. Importantly, CRM1 knockdown inhibits MM cell viability. Novel, oral, irreversible selective inhibitors of nuclear export (SINEs) targeting CRM1 (KPT-185, KPT-330) induce cytotoxicity against MM cells (ED 50 o200 nM), alone and cocultured with bone marrow stromal cells (BMSCs) or osteoclasts (OC). SINEs trigger nuclear accumulation of multiple CRM1 cargo tumor suppressor proteins followed by growth arrest and apoptosis in MM cells. They further block c-myc, Mcl-1, and nuclear factor kB (NF-kB) activity. SINEs induce proteasome-dependent CRM1 protein degradation; concurrently, they upregulate CRM1, p53-targeted, apoptosis-related, anti-inflammatory and stress-related gene transcripts in MM cells. In SCID mice with diffuse human MM bone lesions, SINEs show strong anti-MM activity, inhibit MM-induced bone lysis and prolong survival. Moreover, SINEs directly impair osteoclastogenesis and bone resorption via blockade of RANKL-induced NF-kB and NFATc1, with minimal impact on osteoblasts and BMSCs. These results support clinical development of SINE CRM1 antagonists to improve patient outcome in MM.
INTRODUCTION
Multiple myeloma (MM) is characterized by excess bone marrow plasma cells and monoclonal protein, commonly associated with osteoporosis and lytic bone disease. Although considerable progress has been made in the development of novel treatments for MM, disease relapse occurs in the vast majority of patients. Interactions between MM cells, osteoclasts (OC), and bone marrow stromal cells (BMSC) have a central role in disease pathogenesis and mediate resistance to conventional MM therapies. Therefore, novel targeted therapies with innovative mechanisms of action to inhibit both MM cell growth and OC-mediated bone destruction are urgently needed.
Exportin 1 (XPO1), the key nuclear export protein more commonly called CRM1 (chromosome region maintenance 1), is required for transporting cargo proteins with leucine-rich nuclear export sequences from the nucleus to the cytoplasm. 1 Specifically, the CRM1-cargo complex is actively transported through the nuclear pore complex to the cytoplasm, where the cargo is released after RanGAP-catalyzed GTP hydrolysis. CRM1-mediated shuttling of these proteins is tightly controlled, thereby regulating which proteins are activated or repressed by specific stimuli. Importantly, this process is deregulated at multiple levels in cancer cells, with CRM1-dependent cargo proteins including tumor suppressor (TSP) and regulatory proteins p53, 2,3 p21 CIP , p27 KIP1 , 4 FOXO, 5, 6 inhibitor of nuclear factor kB (NF-kB) (IkB) 7 and BRCA1. 4, 8 These TSPs can only prevent cancer initiation, progression and drug resistance when properly localized inside the nucleus, and are often mutated, deleted or aberrantly located within the cytosol in cancer cells, thereby disabling them from performing their normal functions within the nucleus. Importantly, as CRM1 is the sole nuclear exporter of these proteins, abnormal cellular localization of TSPs in tumors may be mediated by CRM1. Indeed, increased expression of CRM1 is associated with tumor sizes in osteosarcoma, 9 pancreas cancer 10 and ovarian cancer. 11 Moreover, overexpression of CRM1 in lung and cervical cancer cells has a key role in their proliferation and survival. 3, 12 Whole-genome sequencing of chronic lymphocytic leukemia has recently identified recurrent mutations in a highly conserved region of CRM1, 13, 14 suggesting a role of CRM1 in disease pathogenesis of chronic lymphocytic leukemia. At present, it remains unclear whether CRM1 is involved in the pathophysiology of human MM, and whether targeted inhibition of CRM1 may represent a novel therapeutic modality in MM.
Inhibition of CRM1 was first demonstrated using leptomycin B, which restores function of TSPs by preventing their export to the cytoplasm. 15, 16 CRM1 blockade via leptomycin B maintained topoisomerase IIa in the nucleus and greatly enhances the cytotoxic effect of the topoisomerase II inhibitors doxorubicin and VP-16 (etoposide) in doxorubicin-resistant MM cells. 17 However, the clinical development of leptomycin B has been limited by its toxicity and narrow therapeutic window in preclinical animal models. 18 A novel reversible CRM1 inhibitor CBS9106 with improved tolerability was recently identified. 19 In addition, novel orally bioavailable small-molecule selective inhibitors of nuclear export (SINEs) specifically and irreversibly bind to residue Cys528 in the cargo-binding groove of CRM1, thereby abrogate many of its transport functions. 20, 21 Significant anti-tumor activity of these agents has recently been reported in preclinical studies of acute myeloid leukemia and chronic lymphocytic leukemia. [20] [21] [22] Importantly, SINE KPT-251 and KPT-185 have potent anti-leukemia activity, with negligible toxicity to normal hematopoietic cells. 20, 21 Whether SINEs are effective against human MM is unknown.
In this study, we characterize CRM1 function in MM, and further investigate the efficacy and molecular mechanisms of novel oral SINE CRM1 antagonists in MM. Our studies define the mechanisms whereby these agents inhibit MM cell growth and induce apoptosis in the bone marrow (BM) microenvironment. Moreover, we further define a novel role of CRM1 in OC differentiation, suggesting additional benefits of targeting CRM1 in MM.
MATERIALS AND METHODS

Cell lines, patient sample processing and culture of BMSCs and OCs
All CD138 þ MM cell lines were grown as described previously. 23, 24 Patient MM samples were obtained after informed consent, in accordance with the Declaration of Helsinki and under the auspices of a Dana-Farber Cancer Institute Institutional Review Board-approved protocol. CD138 þ plasma cells from MM patients were purified by CD138-microbeads (Miltenyi Biotech, Auburn, CA, USA). Residual CD138-negative cells were cultured in RPMI 1640/10% FCS to generate BMSCs or stimulated with M-CSF/RANKL for OC differentiation. 23, 24 Lentiviral CRM1 small hairpin RNA (shRNA) transduction CRM1 shRNA vs control pLKO.1 (shCNT) or GFP (shGFP) lentivirus (RNAi Consortium at Dana-Farber Cancer Institute) 25 were transduced into MM cell lines. Three days post transduction, Caspase-Glo 3/7 (Promega, Madison, WI, USA) and CellTiter-Glo Luminescent Cell Viability Assays (Promega) were performed. SINE KPT-185 was characterized most extensively in in vitro assays, [20] [21] [22] but has poor PK properties unsuitable for use in vivo. KPT-251 and -276 are less potent against CRM1 than KPT-185, but have similar specificity and good oral bioavailability, thereby suitable for in vivo studies. [20] [21] [22] KPT-330, nearly as potent as KPT-185, has optimal oral bioavailability and systemic exposure, and is therefore currently undergoing Phase 1 testing in patients with advanced hematologic and solid tumor malignancies.
Immunoblotting
Antibodies were obtained from Cell Signaling (Danvers, MA, USA), except anti-CRM1 and -c-maf Abs (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Immunofluorescence analysis MM1S cells were treated with KPT-185, fixed with 1% paraformaldehyde, permeabilized with 0.05% Triton and stained with indicated antibody to detect individual TSP (green) and with 4 0 -6-diamidino-2-phenylindole (Life Technologies, Carlsbad, CA, USA) to detect nuclei (blue).
Cell cycle profiling and apoptosis assays MM cells were treated with SINEs, followed by staining with 5-bromo-2-deoxyuridine/propidium iodide (PI) and flow cytometric analysis. Apoptosis was measured by annexin V/PI staining and flow cytometric analysis, as well as by Caspase-Glo Assay.
NF-kB p65 DNA-binding activity MM cells and CD14 þ OC precursor (OCP) cells were pretreated with KPT-185 or KPT-330 for 2 h and stimulated with a proliferation-inducing ligand (APRIL, 400 ng/ml, R&D Systems, Minneapolis, MN, USA) and RANKL (100 ng/ml, R&D Systems), respectively. Nuclear protein was then extracted for NF-kB activity using TransAM NF-kB p65 ELISA Kit (Active Motif, Carlsbad, CA, USA).
Cytokine measurements
Multiplex cytokine measurements were done using the Luminex 200 system (EMD Millipore, Billerica, MA, USA).
Real-time quantitative reverse transcription-PCR RNA was extracted from cells and mRNA for indicated genes was quantified using the ViiA7 Real-Time PCR System and analyzed by the V1.2 software (Life Technologies).
Disseminated MM model
All experimental procedures and protocols were approved by the Institutional Animal Care and Use Committee (Dana-Farber Cancer Institute). SCID-beige mice were injected intravenously with 5 Â 10 6 MM1S-LucNeo (MM1Sluc) cells and imaged 2 weeks later to determine baseline bioluminescence. Mice were divided into three groups with similar mean bioluminescence (n ¼ 8 per group): mice received KPT-251 or KPT-276 (each at 50 mg/kg), or vehicle (0.5% (w/v) Pluronic F-68, 0.5% (w/v) PVP K-29/32 in sterile water) via oral gavage three times per week on nonconsecutive days. On day 10, KPT-251 and KPT-276 were both dose intensified to 75 mg/kg. Weight and bioluminescence data were collected every 4-8 days for one month, at which point mice were killed due to hind limb paralysis.
Some mice were killed after the second dose. BM cells were collected for apoptosis assays for MM1Sluc cells. Extremities were collected from these mice and tissue sections were prepared for histologic and immunohistochemical analysis for CD138, p53 and cleaved caspase-3.
Statistical analysis
In vitro experiments were performed in triplicate and repeated at least two times; a representative experiment is shown (mean±s.d.). Statistical significance of differences (set at Po0.05) was determined using one-way analysis of variance with Bonferroni's post hoc comparison (for more than three groups) or a two-tailed unpaired Student's t-test (for two groups) in GraphPad Prism version 4.0 (GraphPad Software, San Diego, CA, USA).
RESULTS
CRM1 is highly expressed in MM cells and associated with survival and bone lysis High CRM1 protein expression was first shown by immunoblotting in CD138 þ patient MM cells (n ¼ 8) and MM cell lines (n ¼ 12; Figure 1a ). Gene expression analyses demonstrated increased CRM1 expression in newly diagnosed MM cells (n ¼ 351) vs normal plasma cells (n ¼ 22; Po0.001 under accession number GSE5900 (ref. 26) and GSE2658 (refs. 27,28) in Figure 1b ; P ¼ 0.01 in GSE6691 (ref. 29) in Supplementary Figure 1A ) and in plasma cell leukemia vs MM (Po0.01 in GSE2113, 30 Supplementary Figure 1A) . Interestingly, CRM1 transcript is also higher in patients unresponsive to bortezomib treatment (Po0.004 in GSE9872, Figure 1c ). 31 The correlation of CRM1 expression and survival was further determined by the P-value and hazard ratio at the best expression signal cutoff using R-package under GSE2658. 27, 28 Higher CRM1 is significantly associated with a poor outcome (P ¼ 0.024 for eventfree survival and P ¼ 0.044 for overall survival, Figure 1d ) and the extent of bone lytic lesion in the Total Therapy 2 cohort (P ¼ 0.008, Targeting CRM1 in the myeloma bone marrow microenvironment Y-T Tai et al Figure 1d ). These results suggest that elevated CRM1 expression is important for MM pathophysiology. Figure 1D) . Thus, CRM1 function is critical for maintenance of malignant growth and survival of MM cells.
SINEs targeting CRM1 induce growth arrest and apoptosis in MM cells associated with nuclear accumulation of multiple TSP genes As the effects of KPT-185 mimicked those of CRM1 shRNA, we determined whether small-molecule, drug-like, selective CRM1 RPMI8226   MM1S  MM1R  INA6  INA6GFP  ANBL6  KMS20  KMS18  MOLP8  28BM  12PE  XG1 whereas KPT-330, currently in phase 1 clinical trials, is nearly as potent as KPT-185 and has optimal PK properties. Multiple MM cell lines were incubated with KPT-185 or KPT-330 for 2 days, followed by a luminescence cell viability assay (Figures 3a, b) . Both SINEs reduced cell viability, with ED 50 s for KPT-185 and KPT-330 of o100 ando220 nM, respectively. Additional assays further confirmed that KPT-185 and KPT-330 potently inhibited growth and survival of MM cells, regardless of their drug sensitivity or p53 status (Supplementary Figure 2) .
Next, cell cycle analyses showed that three SINEs similarly decreased S-phase proliferating MM1S cells, followed by an increase in sub-G1 apoptotic cells (Figure 3c ). Using immunofluorescence staining, prominent nuclear accumulation of p53 and IkB occurred as early as 2 h after KPT-185 treatment (Figure 3d ). Nuclear localization of p27, a downstream target of p53 and FOXO3A signaling important for growth arrest and apoptosis, as well as FOXO1A and PP2A was evident at later time points (16 h). Immunoblotting of nuclear vs cytoplasmic extracts prepared from MM1S cells following KPT-330 treatment further confirmed nuclear accumulation of p53, IkB, p21 and p27 (Figure 3e ). Brg-1 validated purity of nuclear extract preparation as Brg-1 is undetectable in cytoplasmic extract. Similar results were obtained in MM1R cells treated with KPT-185 or KPT-330 (data not shown).
Overnight treatment with KPT-185 induced a 9-to 10-fold increase in apoptotic MM1S cells, as combined % of annexin V þ and annexin V þ /PI þ cells is 2.2% (control) vs 18.9% at 0.2 mM KPT-185 and 28.4% at 0.5 mM KPT-185 (Figure 3f ). Because these four SINEs specifically block CRM1 and their effects are similar to those in the shRNA experiments described above, it is likely that CRM1 inhibition itself, rather than an off-target effect, mediates anti-MM properties. Figure 4C ). This induction in CRM1 mRNA following treatment with SINEs is likely in response to loss of CRM1 functional activity, and may therefore provide a useful biomarker for SINE action. In addition to increased CRM1 mRNA triggered by overnight treatment with KPT-185 (0-200 nM), p53, p21, PUMA, BAX, CHOP, C10orf10, MIC1 and IkBa were also increased in MM1S cells, cultured alone and in the presence of BMSCs (Figures 5b, c) . Therefore, SINEs targeting CRM1-modulated expression levels of CRM1 cargoes in MM cells, thereby regulating various functions including cell cycle and apoptosis, as well as stress responses.
NF-kB is activated in MM and contributes to tumor growth, survival and drug resistance, as well as OC activation and osteolysis. As KPT-185 induced nuclear accumulation of IkBa, we next examined whether KPT-185 blocks NF-kB activity in MM cells. KPT-330 (2 h treatment) decreased baseline NF-kB p65 activity in nuclear protein extracted from MM1S and MM1R cells (Figure 5d Figure 4D) . As APRIL, a BM cytokine, activates NF-kB to support MM cell growth and survival, [32] [33] [34] these results suggest that SINEs-induced inhibition of NF-kB is crucial for the decrease in MM viability triggered by these agents in the BM microenvironment.
Because SINE-induced MM cytotoxicity is not significantly attenuated by BMSC and SINEs are not directly cytotoxic to BMSC, we also assessed the effects of CRM1 inhibition on cytokine production by these accessory cells. Overnight treatment with KPT-185 (p100 nM) decreased the secretion of multiple cytokines, including IL-6, VEGF, MIP1b, IL-10, from BMSCs, cultured alone or with MM cells (Figure 5e and Supplementary Figure 4E (two doses at 75 mg/kg) induced MM1Sluc tumor cell death and cleavage of caspase-3 in vivo (Figure 6a ). This was confirmed by a 43-fold increase in % of annexin V þ and annexin V þ /PI þ cells, as well as 1.8-to 3-fold higher caspase-3/7 activity in MM1Sluc tumors harvested from SINE-vs vehicle control-treated mice (Supplementary Figures 5A, B) . Immunohistochemical studies further showed increased p53 and cleaved caspase-3 in tumors excised from SINE-vs control vehicle-treated mice (Figure 6b ).
In longer-term studies in this model, KPT-251 or KPT-276 treatment reduced tumor burden (Figure 6c Figure 5D) . A significant survival benefit was seen in KPT-251-and KPT-276-treated vs vehicle-treated mice: 35 days for SINE-treated vs 23 days for vehicle-treated mice (log-rank test, Po0.005; Figure 6d ). There was no difference in tumor burden or survival between KPT-251 and KPT-276 groups. In addition, KPT-330 treatment also completely blocked MM1S tumor growth in a murine subcutaneous xenograft model (Supplementary Figure 5E , n ¼ 8 for each group). These results indicate that these SINEs CRM1 antagonists show comparable anti-MM effects in vivo.
High-resolution CT imaging of the mice bearing disseminated MM1Sluc tumors further showed marked MM-induced osteolysis and reduction in bone mineral density in vehicle-treated animals ( Figure 6e ). In contrast, improvement of bone lesions resembling control mice with no MM1Sluc tumor cell injection was observed in SINE-treated vs vehicle-treated mice.
SINEs further prevent OC differentiation and bone resorption via inhibition of NF-kB and NFATc1
We further investigated whether the effects of SINEs on bone were mediated only through anti-MM activity, or by additional direct effects on osteoclastogenesis. As NF-kB activation by essential OC differentiation cytokine RANKL along with NFATc1 (ref. 36) control osteoclastogenesis, we examined whether SINEs inhibit these key OC regulators to block OC formation. KPT-330 blocked RANKLinduced NF-kB p65 activity in CD14 þ OC precursor cells (Figure 7a ). KPT-330 also blocked RANKL-induced phosphorylation of p65 (Figure 7b ), further indicating an inhibition of NF-kB signaling cascade. As expected, RANKL/M-CSF profoundly induced NFATc1 after 5 days; importantly, KPT-330 blocked NFATc1 induction at both protein and transcriptional levels (Figures 7b, c) . Using real-time quantitative reverse transcription-PCR, downstream targets of NF-kB and NFATc1 that are crucial for adhesion, fusion and function of preosteoclasts, including ACP5/TRAP, integrinb3 (ITGb3), ITGav, DC-STAMP (DCST1), 37, 38 were also downregulated (Figure 7c ). KPT-185 also produced similar effects on these OC-related molecules (Supplement Figures 6A-C) In 3-week MM patient OC cultures (n ¼ 4), KPT-185 significantly reduced the number of TRAP þ multinucleated mature OC cells (Figure 7d) , consistent with decreased secretion of TRAP5b, a specific mature OC marker 23 ( Supplementary Figures 6D, E) . Immunofluorescence staining of the actin cytoskeleton and nucleus further showed that SINEs inhibit actin belt formation crucial for mature OC function; and prevent fusion of preosteoclasts, thereby decreasing the number of multinucleated mature OC (Figure 7e, Supplementary Figure 6F) . Finally, pit formation assays on dentine slices confirmed that either KPT-185 or KPT-330 significantly impaired % erosion area (Figure 7f, Supplementary  Figure 6G ).
We simultaneously assessed the effect of SINEs on osteogenesis derived from mesenchymal stem cells of normal healthy donors (n ¼ 3). KPT-330 blocked calcium deposition (Figure 7g calcium deposition from osteoblasts (Supplementary Figure 6H) . Thus, SINEs specifically blocked OC formation and their bone resorption activity, without adverse effects on bone formation activity.
DISCUSSION
We first show that high CRM1 expression in CD138 þ MM patient cells is associated with lytic bone disease and shorter survival, and that bortezomib-resistant patient MM cells express higher CRM1 levels, suggesting a pathogenic role of CRM1 in MM. Using four separate shCRM1 lentiviruses targeting four different regions in CRM1 gene in several MM cell lines, we observed that the degree of CRM1 downregulation correlated with levels of apoptosis. Thus, CRM1 function is critical for the maintenance of malignant growth and survival of MM cells, consistent with a recent report of CRM1/XPO1 as a MM survival gene. 39 We then showed that blocking CRM1 using SINEs (KPT-185, KPT-251, KPT-276, and KPT-330) induced growth arrest and apoptosis in MM cells, alone and cultured with BMSC or OC. KPT-185 and KPT-330 further inhibited NF-kB activity in MM and OC lineage cells, thereby overcoming tumor cell growth and drug resistance in the BM milieu. Importantly, this is the first report to define a novel role of CRM1 in OC formation, as CRM1 knockdown significantly blocks the key OC differentiation regulator NFATc1 induced by RANKL. KPT-185 and KPT-330 consistently inhibit both NF-kB activity and OC differentiation genes downstream of NFATc1 (ACP5/TRAP, ITGav, ITGb3 and DCST1), thereby preventing adhesion and fusion of preosteoclasts to form functional OC. These results therefore provide compelling evidence to target CRM1 to both induce apoptosis in MM cells and improve bone disease. The mechanisms of CRM1 inhibition-mediated cytotoxicity of these SINEs in MM cells were delineated. SINEs rapidly reduced S-phase proliferating MM1S cells, followed by increased sub-G1 apoptotic cells. As shown by immunofluorescence staining and immunoblotting of nuclear and cytoplasmic lysates, cycling MM1S cells express low overall, with low nuclear and high cytoplasmic level, of key TSP proteins including p53, IkB, FOXO1A, FOXO3A, p27 and PP2A. Importantly, KPT-185 and KPT-330 potently restored nuclear localization and elevated levels of these TSPs in MM1S cells. Transcripts of p53 and its downstream targets p21, BAX, PUMA were also induced by KPT-185, indicating that nuclear localization of p53 leads to activation of its TSP function. PUMA, which is dramatically (16-to 45-fold) upregulated by KPT-185 in MM1S cells, is also regulated by a p53-independent mechanism to induce apoptosis in vivo. 40 For example, FOXO3a upregulates PUMA in response to a p53-independent apoptotic stimuli. were performed on glass coverslips, followed by immunofluorescence staining using Alexa 568-conjugated phalloidin for actin (red) and 4 0 -6-diamidino-2-phenylindole for nuclei (blue). Extended spreading area per multinucleated OC (43 nuclei) and number of nuclei per OC was reduced in a dose-dependent manner. (f ) OC culture was performed on dentine slices with and without KPT-330 for 3 weeks. Bright-field images of dried dentine discs were then acquired and processed with Photoshop 7.0 to obtain a binary image. Bone pits were shown by black pixels (upper panels). The percentage of the area occupied by black pixels corresponds to the % bone erosion area (lower panel). *Po0.05; **Po0.001. (g) Human osteoprogenitor cells derived from normal donors (n ¼ 3) were cultured in osteogenic media, with or without KPT-330. Calcium deposition by Alizarin red was quantified by ELISA at the end of 21-day culture. Representative images of Alizarin red staining are shown; scale bars represent 200 mm.
As KPT-185 also induces nuclear accumulation of FOXO3a, it further enhances PUMA expression. Increased PUMA via FOXO3a may therefore contribute to KPT-185-induced cell death in MM cells harboring mutated p53. Along with increased pro-apoptotic PUMA and BAX, KPT-185 also decreased anti-apoptotic proteins Mcl-1 and Bcl-xL in MM cells, consistent with cytotoxicity of SINEs against tumor cells resistant to conventional therapy. Mcl-1 is regulated by NF-kB and mediates survival and drug resistance in MM, 39 further highlighting the potential clinical utility of its inhibition by SINEs. Importantly, KPT-251 and KPT-276 significantly increased p53 and cleaved caspase-3 in MM1S tumors growing within the bones of SCID mice, confirming drug-related induction of tumor cell apoptosis in vivo.
Surprisingly, SINEs reduced levels of MM growth drivers and oncogenes including c-myc. The nuclear export of c-myc is not mediated by CRM1, 42 and it is not clear why CRM1 inhibition led to c-myc reduction. A recent study reported that c-myc and CRM1 are coordinately regulated, and that p53 activation reduces levels of both genes. 43 This observation is consistent with the presence of a p53 repressive-binding site in the CRM1 promoter. 44 Interestingly, treatment of acute myeloid leukemia with KPT-185 was recently reported to downregulate the oncogenic drivers Flt3 and Kit, 22 which is not due to a general increase in protein degradation as p53, p21, IkB and other proteins are increased. Moreover, SINE treatment elevates levels of the pro-apoptotic genes BAX and PUMA, whereas reducing the anti-apoptotic proteins Mcl-1. Thus, it is likely that nuclear entrapment of TSPs protects them from cytoplasmic proteasome-mediated degradation; and conversely, that CRM1 inhibition can drive the destruction of oncogenic proteins.
SINEs induce broad anti-tumor activity in MM. They are active against MM cells harboring mutated p53, which occurs in 470% in MM cell lines and increasingly in the setting of relapsed and refractory MM. These results indicate p53-independent mechanisms whereby SINEs mediate their anti-cancer activity. Blockade of NF-kB activation by SINE could mediate p53-independent SINEinduced MM cytotoxicity, in addition to PUMA induction described above. Importantly, SINEs inhibit NF-kB p65 DNA-binding activity, which may account, at least in part, for the ability of SINEs to overcome MM cell growth and conventional drug resistance conferred by the BM milieu. Specifically, NF-kB is implicated in mediating intrinsic drug resistance in MM 45 and other tumors, as well as regulating adhesion molecule expression on MM and BM accessory cells mediating their interaction and binding, which confers resistance to conventional chemotherapy in our study. KPT-185 and KPT-330 blocked NF-kB p65 activity, at least in part, by increasing nuclear IkB levels and inhibiting pIkB in both MM cells and OC precursors. Inhibition of RANKL-induced NF-kB activity in OC precursors further blocked expression of early OC differentiation gene ACP5 and NFATc1. Interestingly, SINEs caused minimal apoptosis of BMSCs and osteoblasts at the concentrations which trigger 480% MM cell apoptosis (42-log differences), consistent with the minimal effects of SINEs on other nonneoplastic cell types. 20, 21 Significantly, SINEs reduced secretion of cytokines supporting MM cell growth, survival, drug resistance and angiogenesis, including IL6, VEGF, MIP-1b and IL-10, from BMSCs, alone or in cocultures with MM cells. As production of many of these MM growth factors/cytokines occurs via NF-kBdependent paracrine mechanisms in BMSCs, SINE-induced inhibition of NF-kB activity in BMSCs and other accessory cells may contribute to their cytotoxicity against MM cells in the BM microenvironment.
In addition to BMSCs, osteoprogenitor cells are also less sensitive to SINEs than either MM cells or OCs. Although inhibiting osteoclastogenesis, SINEs had no impact on osteogenesis in vitro and did not further decrease MM cell-suppressed calcium deposition from osteoblasts, suggesting that SINEs did not affect new bone formation. These observations, along with the minimal toxicity of SINEs on normal hematopoietic cells, that is, CD34 þ progenitor, NK, T cells, 20, 21 suggest that SINEs may have a more favorable therapeutic window than previously identified CRM1 inhibitors. 46 Furthermore, KPT-330, currently in phase 1 trials in advanced malignancies, showed no significant effect on normal immunoglobulin levels in studies in monkeys and rats treated over 28 days with 14-day recovery (Shacham et al., unpublished observations). These observations indicate that SINE CRM1 antagonists show improved selectivity for neoplastic vs normal cell types, and may therefore have a favorable side-effect profile.
In summary, this study defines a role of CRM1 elevation in MM pathophysiology, both tumor cell growth and drug resistance as well as OC differentiation. Importantly, SINE treatment induced potent and rapid apoptosis of MM cells in vitro and in vivo, and further directly decreased bone resorption. These data therefore provide the preclinical rationale for ongoing clinical development of the oral KPT-330 to improve patient outcome and decrease bone disease in MM (Clinical Trial: NCT01607892).
